483
Eli Lilly & CompanyEli Lilly & Company – FDA 483, Oct 6, 2023
Record Details
Eli Lilly and Company in Indianapolis, Indiana, received a Form 483 with three observations related to sterile drug product manufacturing. The observations highlight deficiencies in preventing microbiological contamination, inadequate sterilization process validation, and an unoptimized drug product fill process leading to encrustation. These issues indicate significant concerns regarding aseptic processing and product quality control.
View Company Profile
ID · f0349542-8a47-4147-9164-7ecacf1fcd4e
Other documents for Eli Lilly & Company
Document or profile
One record shows the event. A profile shows the pattern.
Buy this document for the source file and details behind this single event.
Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.